Worth reading
23Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedKey initiatives
01Conduct a clinical trial consultation with the PMDA during fiscal 2026
02Conduct a small-scale dose-confirmation study in Asians, primarily Japanese, in 2027
03Start a domestic Phase III clinical trial in 2029
04Begin development in Japan with a small-scale dose-confirmation study in Asians, primarily Japanese, and then move promptly to a domestic Phase III clinical trial
05Continue considering commercialization, including future clinical development and out-licensing
Plan assumptionsClinical trials must be conducted in accordance with Japanese regulatory requirements, Make maximum use of development data accumulated overseas to date
Risks identified by the company
Conducting clinical trials in accordance with Japanese regulatory requirements
Development costs
Development risks
Reason for revision or withdrawal
Following the capital and business alliance with Senju Pharmaceutical Co., Ltd., the policy was changed to prioritize development in Japan. A development plan has been adopted that aims to obtain approval while making maximum use of development data accumulated overseas to date and containing the development costs and risks required before commercialization.
| Item | Details |
|---|---|
| Plan name | Domestic Development Plan for the Glaucoma Treatment H-1337 |
| Progress against the plan | Formulated |
| Plan assumptions | Clinical trials must be conducted in accordance with Japanese regulatory requirements, Make maximum use of development data accumulated overseas to date |
| Key initiatives | Conduct a clinical trial consultation with the PMDA during fiscal 2026, Conduct a small-scale dose-confirmation study in Asians, primarily Japanese, in 2027, Start a domestic Phase III clinical trial in 2029, Begin development in Japan with a small-scale dose-confirmation study in Asians, primarily Japanese, and then move promptly to a domestic Phase III clinical trial, Continue considering commercialization, including future clinical development and out-licensing |
| Reason for revision or withdrawal | Following the capital and business alliance with Senju Pharmaceutical Co., Ltd., the policy was changed to prioritize development in Japan. A development plan has been adopted that aims to obtain approval while making maximum use of development data accumulated overseas to date and containing the development costs and risks required before commercialization. |
| Risks identified | Conducting clinical trials in accordance with Japanese regulatory requirements, Development costs, Development risks |
| Date of board resolution | 3 September 2026 |
| Publication date | 3 September 2026 |
Items this document does not state (17)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The policy was changed to prioritize development in Japan following the capital and business alliance with Senju Pharmaceutical Co., Ltd. The aim is to obtain approval while making maximum use of development data accumulated overseas and containing the development costs and risks required before commercialization.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.